CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00056990" target="_blank" >RIV/00216224:14110/11:00056990 - isvavai.cz</a>
Výsledek na webu
—
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
čeština
Název v původním jazyce
CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
Popis výsledku v původním jazyce
Cytochrome P450, namely CYP2D6 is major metabolizing enzyme for many antipsychotics, including risperidone. The aim of present study was to evaluate in 35 patients with first episode of schizophrenia relation of genotype and phenotype of CYP2D6 to therapeutic response to risperidone treatment and occurrence of adverse effects. PANSS score was assessed weekly; as response was considered at least 30 % reduction of baseline of total PANSS score; CYP2D6 genotype was assessed by automatic sequencing of DNA isolated from peripheral leukocytes, phenotype was assessed using dextromethorphan as a probe substrate.
Název v anglickém jazyce
CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
Popis výsledku anglicky
Cytochrome P450, namely CYP2D6 is major metabolizing enzyme for many antipsychotics, including risperidone. The aim of present study was to evaluate in 35 patients with first episode of schizophrenia relation of genotype and phenotype of CYP2D6 to therapeutic response to risperidone treatment and occurrence of adverse effects. PANSS score was assessed weekly; as response was considered at least 30 % reduction of baseline of total PANSS score; CYP2D6 genotype was assessed by automatic sequencing of DNA isolated from peripheral leukocytes, phenotype was assessed using dextromethorphan as a probe substrate.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
FR - Farmakologie a lékárnická chemie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NS9676" target="_blank" >NS9676: Vliv farmakogenetických a farmakokinetických faktorů na účinnost a bezpečnost terapie prvních epizod schizofrenie</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2011
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů